IMMUNOMET THERAPEUTICS INC has a total of 38 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2012. It filed its patents most often in United States, EPO (European Patent Office) and Republic of Korea. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are FAB PHARMA S A S, BOEHM MARCUS F and MEBIAS DISCOVERY INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 14 | |
#2 | EPO (European Patent Office) | 6 | |
#3 | Republic of Korea | 6 | |
#4 | China | 3 | |
#5 | WIPO (World Intellectual Property Organization) | 3 | |
#6 | Canada | 2 | |
#7 | Hong Kong | 2 | |
#8 | Japan | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Acyclic or carbocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Lee Ji Sun | 29 |
#2 | Kim Sung Wuk | 27 |
#3 | Heo Hye Jin | 27 |
#4 | Kim Hong Woo | 25 |
#5 | Lee Hong Bum | 24 |
#6 | Kook Ji Ae | 18 |
#7 | Lee Young Woo | 15 |
#8 | Yoo Sang Hee | 13 |
#9 | Jeong Jae Kap | 10 |
#10 | Min Chang Hee | 8 |
Publication | Filing date | Title |
---|---|---|
KR20210014090A | Biguanide compounds and use thereof | |
HK1252052A1 | Guanidine compounds and use thereof | |
WO2017188694A1 | Heteroaryl compound comprising nitrogen, and use thereof | |
KR20170019814A | New IDO-1 INHIBITOR AND USE THEREOF | |
KR20160134932A | Pharmaceutical composition comprising a biguanide derivative as an active ingredient for preventing or treating glioblastoma | |
WO2016175357A1 | Guanidine compounds and use thereof | |
US2017073331A1 | Guanidine compounds and use thereof | |
KR20160060512A | Biguanide compounds and use thereof | |
US2015368198A1 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |